Loading…
Reported covered position: Sen. Breaux, House MMF Comm., Cong. McCrery
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Drug Safety Enhancement Act of 2011
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
Prescription Drug User Fee Act Reauthorization; FDA Sentinel Pilot; S. 319 Pharmaceutical Market Access and Drug Safety Act; H.R.2245, Preserving Access to Life-Saving Medications Act of 2011; DTC advertising; HR 1483 Drug Import Safety legislation; drug pedigree, U.S. and foreign supply chain and drug shortage issues; Safeguarding Americas Pharmaceuticals Act; counterfiet and serialization; labeling, Best Pharmaceuticals Research Act, Pediatric Research Equity Act, Accelerated approvals, TREAT Act
Medicare Drug Savings Act of 2011
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
TAKEDA PHARMACEUTICALS AMERICA INC via TAKEDA PHARMACEUTICALS AMERICA, INC.
2012 · second_quarter · 2A
Importation issues; Preserve Access to Affordable Generics Act; S. 319 Pharmaceutical Market Access and Drug Safety Act; Drug Import Safety issues; foreign drug supply chain issues; counterfiet drugs, serialization and development of tracibility model
Implications of ACA and Supreme Court decision; depression Rx access in Medicare, Medicaid, DOD, VA; lack of obesity Rx access in Part D;
Source: Senate LDA
340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; Debt and deficit negotiations S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; the Medicaid Improvement and State Empowerment Act; Academic Detailing; S. 1699 Prescription Drug Cost Reduction Act; HR 3765 Temporary Payroll Tax Cut Continuation Act; HR 3765 Conflict of interest provisions; Tax Relief and Job Creation Act of 2012 (H.R. 3630); Cong. Ryan and President Obama budget proposals
Medicare Drug Savings Act of 2011
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
Implementaton of ACA Pharmaceutical fee; corporate tax reform, R&D tax credit extension; Debt commissions recommendations; Reid/Baucus Lundgren repeal of Patient Protection and Affordable Care Act; Innovate America Act; Ryan Roadmap; Debt and deficit negotiations; foreign tax reforms; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; S. 1577 R&D Credit Bill; Camp International Tax Reform draft; Tax Relief and Job Creation Act of 2012 (H.R. 3630);
Preserving Access to Life-Saving Medications Act of 2011
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
Prescription Drug User Fee Act Reauthorization; FDA Sentinel Pilot; S. 319 Pharmaceutical Market Access and Drug Safety Act; H.R.2245, Preserving Access to Life-Saving Medications Act of 2011; DTC advertising; HR 1483 Drug Import Safety legislation; drug pedigree, U.S. and foreign supply chain and drug shortage issues; Safeguarding Americas Pharmaceuticals Act; counterfiet and serialization; labeling, Best Pharmaceuticals Research Act, Pediatric Research Equity Act, Accelerated approvals, TREAT Act
Temporary Payroll Tax Cut Continuation Act of 2011
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; Debt and deficit negotiations S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; the Medicaid Improvement and State Empowerment Act; Academic Detailing; S. 1699 Prescription Drug Cost Reduction Act; HR 3765 Temporary Payroll Tax Cut Continuation Act; HR 3765 Conflict of interest provisions; Tax Relief and Job Creation Act of 2012 (H.R. 3630); Cong. Ryan and President Obama budget proposals
To amend the Federal Water Pollution Control Act to remove the Administrator of the Environmental Protection Agency's authority to disapprove after a permit has been issued by the Secretary of the Army under section 404 of such Act.
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; Debt and deficit negotiations S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; the Medicaid Improvement and State Empowerment Act; Academic Detailing; S. 1699 Prescription Drug Cost Reduction Act; HR 3765 Temporary Payroll Tax Cut Continuation Act; HR 3765 Conflict of interest provisions; Tax Relief and Job Creation Act of 2012 (H.R. 3630); Cong. Ryan and President Obama budget proposals
To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs.
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
General comparative effectiveness issues, health reform and the un/underinsured, chronic disease legislation (diabetes, mental health, obesity, CKD, value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; PCORI; Essential benefits package, ESRD bundling implementation; coverage gap, S. 371/HR741 Bill to prohibit authorized generics,
College Student Relief Act of 2007
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
health reform and the un/underinsured and implications of ACA SCOTUS decision; chronic disease legislation (diabetes, mental health, obesity, CKD); value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; HR 5 IPAB repeal;
College Student Relief Act of 2007
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
health reform and the un/underinsured and implications of ACA SCOTUS decision; chronic disease legislation (diabetes, mental health, obesity, CKD); value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; HR 5 IPAB repeal;
Drug Safety Enhancement Act of 2011
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
Prescription Drug User Fee Act Reauthorization; FDA Sentinel Pilot; S. 319 Pharmaceutical Market Access and Drug Safety Act; H.R.2245, Preserving Access to Life-Saving Medications Act of 2011; DTC advertising; HR 1483 Drug Import Safety legislation; drug pedigree, supply chain/shortage issues; Safeguarding Americas Pharmaceuticals Act; counterfiet and serialization;
Drug Safety Enhancement Act of 2011
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
Prescription Drug User Fee Act Reauthorization; FDA Sentinel Pilot; S. 319 Pharmaceutical Market Access and Drug Safety Act; H.R.2245, Preserving Access to Life-Saving Medications Act of 2011; DTC advertising; HR 1483 Drug Import Ssafety legislation;
Drug Safety Enhancement Act of 2011
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
Prescription Drug User Fee Act Reauthorization; FDA Sentinel Pilot; S. 319 Pharmaceutical Market Access and Drug Safety Act; H.R.2245, Preserving Access to Life-Saving Medications Act of 2011; DTC advertising; HR 1483 Drug Import Safety legislation; drug pedigree, supply chain/shortage issues; Safeguarding Americas Pharmaceuticals Act; counterfiet and serialization;
Drug Safety Enhancement Act of 2011
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
Prescription Drug User Fee Act Reauthorization; FDA Sentinel Pilot; S. 319 Pharmaceutical Market Access and Drug Safety Act; H.R.2245, Preserving Access to Life-Saving Medications Act of 2011; DTC advertising; HR 1483 Drug Import Safety legislation; drug pedigree, supply chain/shortage issues; Safeguarding Americas Pharmaceuticals Act; counterfiet and serialization;
Drug Safety Enhancement Act of 2011
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
Prescription Drug User Fee Act Reauthorization; FDA Sentinel Pilot; S. 319 Pharmaceutical Market Access and Drug Safety Act; H.R.2245, Preserving Access to Life-Saving Medications Act of 2011; DTC advertising; HR 1483 Drug Import Safety legislation; drug pedigree, supply chain/shortage issues; Safeguarding Americas Pharmaceuticals Act; counterfiet and serialization;
Repealing the Job-Killing Health Care Law Act
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
General comparative effectiveness issues, health reform and the un/underinsured, chronic disease legislation (diabetes, mental health, obesity, CKD), value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; PCORI; Essential benefits package, ESRD bundling implementation; coverage gap, S. 371/HR741 Bill to prohibit authorized generics, Debt and Deficit negotiations HR 2, Repealing the Job-Killing Health Care Law ; Office of Consumer Information and Insurance Oversight; Essential Benefits Committee; Comparative Effectiveness; Patient Centered Outcomes Research Institute; S. 668 The Health Care Bureaucrats Elimination Act;
Repealing the Job-Killing Health Care Law Act
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
General comparative effectiveness issues, health reform and the un/underinsured, chronic disease legislation (diabetes, mental health, obesity, CKD), value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; PCORI; Essential benefits package, ESRD bundling implementation; coverage gap, S. 371/HR741 Bill to prohibit authorized generics, HR 2, Repealing the Job-Killing Health Care Law ; Office of Consumer Information and Insurance Oversight; Essential Benefits Committee; Comparative Effectiveness; Patient Centered Outcomes Research Institute
Repealing the Job-Killing Health Care Law Act
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
General comparative effectiveness issues, health reform and the un/underinsured, chronic disease legislation (diabetes, mental health, obesity, CKD), value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; PCORI; Essential benefits package, ESRD bundling implementation; coverage gap, S. 371/HR741 Bill to prohibit authorized generics, HR 2, Repealing the Job-Killing Health Care Law ; Office of Consumer Information and Insurance Oversight; Essential Benefits Committee; Comparative Effectiveness; Patient Centered Outcomes Research Institute
Medicare Drug Savings Act of 2011
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
Implementaton of ACA Pharmaceutical fee; corporate tax reform, R&D tax credit extension; Debt commissions recommendations; Reid/Baucus Lundgren repeal of Patient Protection and Affordable Care Act; Innovate America Act; Ryan Roadmap; Debt and deficit negotiations; foreign tax reforms; HR. 2190/S.1206 Medicare Drug Savings Act of 2011
Medicare Drug Savings Act of 2011
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; Debt and deficit negotiations S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; the Medicaid Improvement and State Empowerment Act; Academic Detailing;
Medicare Drug Savings Act of 2011
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; Debt and deficit negotiations S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; the Medicaid Improvement and State Empowerment Act
Medicare Drug Savings Act of 2011
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
Implementaton of ACA Pharmaceutical fee; corporate tax reform, R&D tax credit extension; Debt commissions recommendations; Reid/Baucus Lundgren repeal of Patient Protection and Affordable Care Act; Innovate America Act; Ryan Roadmap; Debt and deficit negotiations; foreign tax reforms; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; S. 1577 R&D Credit Bill; Camp International Tax Reform draft
Medicare Drug Savings Act of 2011
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
Implementaton of ACA Pharmaceutical fee; corporate tax reform, R&D tax credit extension; Debt commissions recommendations; Reid/Baucus Lundgren repeal of Patient Protection and Affordable Care Act; Innovate America Act; Ryan Roadmap; Debt and deficit negotiations; foreign tax reforms; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; S. 1577 R&D Credit Bill
Medicare Drug Savings Act of 2011
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; Debt and deficit negotiations S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; the Medicaid Improvement and State Empowerment Act; Academic Detailing;
Medicare Drug Savings Act of 2011
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; Debt and deficit negotiations S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; the Medicaid Improvement and State Empowerment Act; Academic Detailing; S. 1699 Prescription Drug Cost Reduction Act; HR 3765 Temporary Payroll Tax Cut Continuation Act; HR 3765 Conflict of interest provisions
Medicare Drug Savings Act of 2011
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
Implementaton of ACA Pharmaceutical fee; corporate tax reform, R&D tax credit extension; Debt commissions recommendations; Reid/Baucus Lundgren repeal of Patient Protection and Affordable Care Act; Innovate America Act; Ryan Roadmap; Debt and deficit negotiations; foreign tax reforms; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; S. 1577 R&D Credit Bill
Medicare Drug Savings Act of 2011
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; Debt and deficit negotiations S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; the Medicaid Improvement and State Empowerment Act; Academic Detailing;
Medicare Drug Savings Act of 2011
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
Implementaton of ACA Pharmaceutical fee; corporate tax reform, R&D tax credit extension; Debt commissions recommendations; Reid/Baucus Lundgren repeal of Patient Protection and Affordable Care Act; Innovate America Act; Ryan Roadmap; Debt and deficit negotiations; foreign tax reforms; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; S. 1577 R&D Credit Bill
Functional Gastrointestinal and Motility Disorders Research Enhancement Act of 2011
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
Regenerative Medicines Promotion Act; Gastrointestinal and Motility Disorders Research Enhancement Act (H.R. 2239)
Functional Gastrointestinal and Motility Disorders Research Enhancement Act of 2011
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
Regenerative Medicines Promotion Act; Gastrointestinal and Motility Disorders Research Enhancement Act (H.R. 2239); depression screening, end stage renal disease;
Functional Gastrointestinal and Motility Disorders Research Enhancement Act of 2011
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
Regenerative Medicines Promotion Act; Gastrointestinal and Motility Disorders Research Enhancement Act (H.R. 2239); depression screening, end stage renal disease;
Functional Gastrointestinal and Motility Disorders Research Enhancement Act of 2011
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
Regenerative Medicines Promotion Act; Gastrointestinal and Motility Disorders Research Enhancement Act (H.R. 2239); depression screening, end stage renal disease;
Preserving Access to Life-Saving Medications Act of 2011
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
Prescription Drug User Fee Act Reauthorization; FDA Sentinel Pilot; S. 319 Pharmaceutical Market Access and Drug Safety Act; H.R.2245, Preserving Access to Life-Saving Medications Act of 2011; DTC advertising; HR 1483 Drug Import Safety legislation; drug pedigree, supply chain/shortage issues; Safeguarding Americas Pharmaceuticals Act; counterfiet and serialization;
Preserving Access to Life-Saving Medications Act of 2011
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
Prescription Drug User Fee Act Reauthorization; FDA Sentinel Pilot; S. 319 Pharmaceutical Market Access and Drug Safety Act; H.R.2245, Preserving Access to Life-Saving Medications Act of 2011; DTC advertising; HR 1483 Drug Import Safety legislation; drug pedigree, supply chain/shortage issues; Safeguarding Americas Pharmaceuticals Act; counterfiet and serialization;
Preserving Access to Life-Saving Medications Act of 2011
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
Prescription Drug User Fee Act Reauthorization; FDA Sentinel Pilot; S. 319 Pharmaceutical Market Access and Drug Safety Act; H.R.2245, Preserving Access to Life-Saving Medications Act of 2011; DTC advertising; HR 1483 Drug Import Safety legislation; drug pedigree, supply chain/shortage issues; Safeguarding Americas Pharmaceuticals Act; counterfiet and serialization;
Preserving Access to Life-Saving Medications Act of 2011
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
Prescription Drug User Fee Act Reauthorization; FDA Sentinel Pilot; S. 319 Pharmaceutical Market Access and Drug Safety Act; H.R.2245, Preserving Access to Life-Saving Medications Act of 2011; DTC advertising; HR 1483 Drug Import Ssafety legislation;
Preserving Access to Life-Saving Medications Act of 2011
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
Prescription Drug User Fee Act Reauthorization; FDA Sentinel Pilot; S. 319 Pharmaceutical Market Access and Drug Safety Act; H.R.2245, Preserving Access to Life-Saving Medications Act of 2011; DTC advertising; HR 1483 Drug Import Safety legislation; drug pedigree, supply chain/shortage issues; Safeguarding Americas Pharmaceuticals Act; counterfiet and serialization;
Consolidated Appropriations Act, 2012
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
Agriculture; Labor, HHS; Commerce and Homeland Security Departments Appropriation Bills; Continuing Resolution; Budget Control Act of 2011; Joint Committee on Deficit Reduction; HR 3671 and HR 2112 Consolidated Appropriations Acts;
Temporary Payroll Tax Cut Continuation Act of 2011
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; Debt and deficit negotiations S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; the Medicaid Improvement and State Empowerment Act; Academic Detailing; S. 1699 Prescription Drug Cost Reduction Act; HR 3765 Temporary Payroll Tax Cut Continuation Act; HR 3765 Conflict of interest provisions
To amend the Federal Water Pollution Control Act to remove the Administrator of the Environmental Protection Agency's authority to disapprove after a permit has been issued by the Secretary of the Army under section 404 of such Act.
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap ;
To amend the Federal Water Pollution Control Act to remove the Administrator of the Environmental Protection Agency's authority to disapprove after a permit has been issued by the Secretary of the Army under section 404 of such Act.
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; Debt and deficit negotiations S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; the Medicaid Improvement and State Empowerment Act; Academic Detailing;
To amend the Federal Water Pollution Control Act to remove the Administrator of the Environmental Protection Agency's authority to disapprove after a permit has been issued by the Secretary of the Army under section 404 of such Act.
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; Debt and deficit negotiations S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; the Medicaid Improvement and State Empowerment Act
To amend the Federal Water Pollution Control Act to remove the Administrator of the Environmental Protection Agency's authority to disapprove after a permit has been issued by the Secretary of the Army under section 404 of such Act.
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; Debt and deficit negotiations S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; the Medicaid Improvement and State Empowerment Act; Academic Detailing;
To amend the Federal Water Pollution Control Act to remove the Administrator of the Environmental Protection Agency's authority to disapprove after a permit has been issued by the Secretary of the Army under section 404 of such Act.
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap ;
To amend the Federal Water Pollution Control Act to remove the Administrator of the Environmental Protection Agency's authority to disapprove after a permit has been issued by the Secretary of the Army under section 404 of such Act.
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; Debt and deficit negotiations S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; the Medicaid Improvement and State Empowerment Act; Academic Detailing;
To amend the Federal Water Pollution Control Act to remove the Administrator of the Environmental Protection Agency's authority to disapprove after a permit has been issued by the Secretary of the Army under section 404 of such Act.
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; Debt and deficit negotiations S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; the Medicaid Improvement and State Empowerment Act; Academic Detailing; S. 1699 Prescription Drug Cost Reduction Act; HR 3765 Temporary Payroll Tax Cut Continuation Act; HR 3765 Conflict of interest provisions
To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs.
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
General comparative effectiveness issues, health reform and the un/underinsured, chronic disease legislation (diabetes, mental health, obesity, CKD), value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; PCORI; Essential benefits package, ESRD bundling implementation; coverage gap, S. 371/HR741 Bill to prohibit authorized generics, HR 2, Repealing the Job-Killing Health Care Law ; Office of Consumer Information and Insurance Oversight; Essential Benefits Committee; Comparative Effectiveness; Patient Centered Outcomes Research Institute
To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs.
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
General comparative effectiveness issues, health reform and the un/underinsured, chronic disease legislation (diabetes, mental health, obesity, CKD), value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; PCORI; Essential benefits package, ESRD bundling implementation; coverage gap, S. 371/HR741 Bill to prohibit authorized generics, Debt and Deficit negotiations
To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs.
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
General comparative effectiveness issues, health reform and the un/underinsured, chronic disease legislation (diabetes, mental health, obesity, CKD), value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; PCORI; Essential benefits package, ESRD bundling implementation; coverage gap, S. 371/HR741 Bill to prohibit authorized generics, Debt and Deficit negotiations
To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs.
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
General comparative effectiveness issues, health reform and the un/underinsured, chronic disease legislation (diabetes, mental health, obesity, CKD), value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; PCORI; Essential benefits package, ESRD bundling implementation; coverage gap, S. 371/HR741 Bill to prohibit authorized generics, Debt and Deficit negotiations
To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs.
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
General comparative effectiveness issues, health reform and the un/underinsured, chronic disease legislation (diabetes, mental health, obesity, CKD), value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; PCORI; Essential benefits package, ESRD bundling implementation; coverage gap, S. 371/HR741 Bill to prohibit authorized generics, Debt and Deficit negotiations HR 2, Repealing the Job-Killing Health Care Law ; Office of Consumer Information and Insurance Oversight; Essential Benefits Committee; Comparative Effectiveness; Patient Centered Outcomes Research Institute; S. 668 The Health Care Bureaucrats Elimination Act;
To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs.
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
General comparative effectiveness issues, health reform and the un/underinsured, chronic disease legislation (diabetes, mental health, obesity, CKD), value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; PCORI; Essential benefits package, ESRD bundling implementation; coverage gap, S. 371/HR741 Bill to prohibit authorized generics, Debt and Deficit negotiations
To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs.
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
General comparative effectiveness issues, health reform and the un/underinsured, chronic disease legislation (diabetes, mental health, obesity, CKD), value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; PCORI; Essential benefits package, ESRD bundling implementation; coverage gap, S. 371/HR741 Bill to prohibit authorized generics, HR 2, Repealing the Job-Killing Health Care Law ; Office of Consumer Information and Insurance Oversight; Essential Benefits Committee; Comparative Effectiveness; Patient Centered Outcomes Research Institute
Provider Shield Act of 2011
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
HR 816 Provider Shield Act of 2011 Medical malpractice reforms
Provider Shield Act of 2011
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
HR 816 Provider Shield Act of 2011 Medical malpractice reforms
National Alzheimer's Project Act
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
S. 3036 National Alzheimers Project Act
National Alzheimer's Project Act
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
S. 3036 National Alzheimers Project Act
Setting forth the congressional budget for the United States Government for fiscal year 2010 and including the appropriate budgetary levels for fiscal years 2009 and 2011 through 2014.
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
FY 2010 U.S. Treasury Green Book on Administration; H.Con.Res 85/S.Con.Res. 13 Concurrent Resolution on the Budget for FY2010; HR 2997 FY 2010 Agriculture Appropriations; FY 2010 Homeland Security Department; FY 2010 Commerce State Justice Appropriations
Making further continuing appropriations for fiscal year 2011, and for other purposes.
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
HR 2997 FY 2010 Agriculture Appropriations; FY 2010 Homeland Security Department; FY 2010 Commerce State Justice Appropriations; HR 4899 House Supplemental Appropriations; Continuing Resolutions H3801, HJRes 101, HJRes 105; H3802 through 3/4/11; 2010 Debt Commission
Making further continuing appropriations for fiscal year 2011, and for other purposes.
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
HR 2997 FY 2010 Agriculture Appropriations; FY 2010 Homeland Security Department; FY 2010 Commerce State Justice Appropriations; HR 4899 House Supplemental Appropriations; Continuing Resolutions H3801, HJRes 101, HJRes 105; H3802 through 3/4/11; 2010 Debt Commission
Patent Reform Act of 2009
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
S. 515, S. 610 and HR 1260 Patent Reform Acts, general patent reform and settlement issues, general follow-on-biologic issues, S 1796 America's Healthy Future Act of 2009; Kerry Patent Tax amendment; HR 3590 Patient Protection and Affordable Care Act, HR 4899 House Supplemental Appropriations
Patent Reform Act of 2009
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
S. 515, S. 610 and HR 1260 Patent Reform Acts, general patent reform and settlement issues, general follow-on-biologic issues, S 1796 America's Healthy Future Act of 2009; Kerry Patent Tax amendment; HR 3590 Patient Protection and Affordable Care Act, HR 4899 House Supplemental Appropriations; Senate Financial Services Approproations mark up
Patent Reform Act of 2009
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
S. 515, S. 610 and HR 1260 Patent Reform Acts, general patent reform and settlement issues, general follow-on-biologic issues, S 1796 America's Healthy Future Act of 2009; Kerry Patent Tax amendment; HR 3590 Patient Protection and Affordable Care Act, HR 4899 House Supplemental Appropriations; Senate Financial Services Approproations mark up
Patent Reform Act of 2009
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
S. 515, S. 610 and HR 1260 Patent Reform Acts; H.R. 427 Promoting Innovation and Access to Live-saving Medicine Act, HR 1548 Pathway for Biosimilars Act, S. 726 Licensing of biosimilar/biogeneric products, H.R. 1706 Protecting Consumer Access to Generic Drugs, general patent reform and settlement issues, general follow-on-biologic issues, S 1679 Affordable Health Choices Act, HR 3961Medicare Physician Payment Reform Act of 2009; S 1796 America's Healthy Future Act of 2009; HR 3962 Affordable Health Care for America Act; HR 3590 Senate Leadership's Health Care Overhaul; S 1504 Notice of Pleading Restoration Act of 2009
Water Quality Investment Act of 2009
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
H.R. 1262 Water Quality Investment Act, HR 5320 The Assistance, Quality and Affordability Act,
Water Quality Investment Act of 2009
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
H.R. 1262 Water Quality Investment Act
Medical Device Safety Act of 2009
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
H.R. 1346/S. 540 The Medical Device Safety Act
Medical Device Safety Act of 2009
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
H.R. 1346/S. 540 The Medical Device Safety Act
Pathway for Biosimilars Act
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
S. 301 Physician Payment Sunshine Act, S. 537 Sunshine in Litigation Act, S. 623 The Pre-existing Condition Patient Protection Act, H.R. 427 Promoting Innovation and Access to Life-Saving Medicine Act, H.R. 1548 Pathway for Biosimilars Act, S. 726 Licensing of Biosimilar/Biogeneric Products, general comparative effectiveness issues, general health reform and the un/underinsured, general diabetes legislation, HR 4872 Health Care Reconcilation Act of 2010, HR 3590 Patient Protection and Affordable Care Act S 1679 Affordable Health Choices Act; HR 3961Medicare Physician Payment Reform Act of 2009; S 1796 America's Healthy Future Act of 2009; HR 3962 Affordable Health Care for America Act; HR 3590 Senate Leadership's Health Care Overhaul; H.R. 1995 Eliminating Disparities in Diabetes Prevention Access and Care Act of 2009, FTC Report "Emerging Health Care Issues: Follow-on Bilogic Drug Competition," mental health parity, value based insurance design, quality of care, adhereance.
Pathway for Biosimilars Act
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
S. 515, S. 610 and HR 1260 Patent Reform Acts; H.R. 427 Promoting Innovation and Access to Live-saving Medicine Act, HR 1548 Pathway for Biosimilars Act, S. 726 Licensing of biosimilar/biogeneric products, H.R. 1706 Protecting Consumer Access to Generic Drugs, general patent reform and settlement issues, general follow-on-biologic issues, S 1679 Affordable Health Choices Act, HR 3961Medicare Physician Payment Reform Act of 2009; S 1796 America's Healthy Future Act of 2009; HR 3962 Affordable Health Care for America Act; HR 3590 Senate Leadership's Health Care Overhaul; S 1504 Notice of Pleading Restoration Act of 2009
Protecting Consumer Access to Generic Drugs Act of 2009
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
S. 515, S. 610 and HR 1260 Patent Reform Acts; H.R. 427 Promoting Innovation and Access to Live-saving Medicine Act, HR 1548 Pathway for Biosimilars Act, S. 726 Licensing of biosimilar/biogeneric products, H.R. 1706 Protecting Consumer Access to Generic Drugs, general patent reform and settlement issues, general follow-on-biologic issues, S 1679 Affordable Health Choices Act, HR 3961Medicare Physician Payment Reform Act of 2009; S 1796 America's Healthy Future Act of 2009; HR 3962 Affordable Health Care for America Act; HR 3590 Senate Leadership's Health Care Overhaul; S 1504 Notice of Pleading Restoration Act of 2009
Diabetes in Minority Populations Evaluation Act of 2010
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
S. 301 Physician Payment Sunshine Act, S. 537 Sunshine in Litigation Act, S. 623 The Pre-existing Condition Patient Protection Act, H.R. 427 Promoting Innovation and Access to Life-Saving Medicine Act, H.R. 1548 Pathway for Biosimilars Act, S. 726 Licensing of Biosimilar/Biogeneric Products, general comparative effectiveness issues, general health reform and the un/underinsured, general diabetes legislation, HR 4872 Health Care Reconcilation Act of 2010, HR 3590 Patient Protection and Affordable Care Act S 1679 Affordable Health Choices Act; HR 3961Medicare Physician Payment Reform Act of 2009; S 1796 America's Healthy Future Act of 2009; HR 3962 Affordable Health Care for America Act; HR 3590 Senate Leadership's Health Care Overhaul; H.R. 1995 Eliminating Disparities in Diabetes Prevention Access and Care Act of 2009, FTC Report "Emerging Health Care Issues: Follow-on Bilogic Drug Competition," mental health parity, value based insurance design, quality of care, adhereance.
Food Safety Enhancement Act of 2009
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
HR 759 Food and Drug Administration Globalization Act of 2009, S. 525 Pharmaceutical Market Access and Drug Safety Act of 2009 and General Importation issues, H.R. 2749 Food Safety Safety Enhancement Act, S. 882 The Drug and Device Accountability Act of 2009, Prescription Drug User Fee Act of 2012 preparation
Food Safety Enhancement Act of 2009
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
HR 759 Food and Drug Administration Globalization Act of 2009, S. 525 Pharmaceutical Market Access and Drug Safety Act of 2009 and General Importation issues, H.R. 2749 Food Safety Safety Enhancement Act, S. 882 The Drug and Device Accountability Act of 2009, Prescription Drug User Fee Act of 2012 preparation, general pedigree and chain drug supply issues
Food Safety Enhancement Act of 2009
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
HR 759 Food and Drug Administration Globalization Act of 2009, S. 525 Pharmaceutical Market Access and Drug Safety Act of 2009 and General Importation issues, H.R. 2749 Food Safety Safety Enhancement Act, S. 882 The Drug and Device Accountability Act of 2009, Prescription Drug User Fee Act of 2012 preparation, general pedigree and chain drug supply issues, HR 4678 Foreign Manufacturers Legal Accountiblity Act
Food Safety Enhancement Act of 2009
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
HR 759 Food and Drug Administration Globalization Act of 2009, S. 525 Pharmaceutical Market Access and Drug Safety Act of 2009 and General Importation issues, H.R. 2749 Food Safety Safety Enhancement Act, S. 882 The Drug and Device Accountability Act of 2009, Prescription Drug User Fee Act of 2012 preparation, general pedigree and chain drug supply issues, HR 4678 Foreign Manufacturers Legal Accountiblity Act; H.R. 6543 The Drug Safety Enhancement Act
Notify Americans Before Outsourcing Personal Information Act
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
S. 301 Physician Payment Sunshine Act, S. 537 Sunshine in Litigation Act, S. 623 The Pre-existing Condition Patient Protection Act, H.R. 427 Promoting Innovation and Access to Life-Saving Medicine Act, H.R. 1548 Pathway for Biosimilars Act, S. 726 Licensing of Biosimilar/Biogeneric Products, general comparative effectiveness issues, general health reform and the un/underinsured, general diabetes legislation, HR 4872 Health Care Reconcilation Act of 2010, HR 3590 Patient Protection and Affordable Care Act S 1679 Affordable Health Choices Act; HR 3961Medicare Physician Payment Reform Act of 2009; S 1796 America's Healthy Future Act of 2009; HR 3962 Affordable Health Care for America Act; HR 3590 Senate Leadership's Health Care Overhaul; H.R. 1995 Eliminating Disparities in Diabetes Prevention Access and Care Act of 2009, FTC Report "Emerging Health Care Issues: Follow-on Bilogic Drug Competition," mental health parity, value based insurance design, quality of care, adhereance.
Notify Americans Before Outsourcing Personal Information Act
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
S. 515, S. 610 and HR 1260 Patent Reform Acts; H.R. 427 Promoting Innovation and Access to Live-saving Medicine Act, HR 1548 Pathway for Biosimilars Act, S. 726 Licensing of biosimilar/biogeneric products, H.R. 1706 Protecting Consumer Access to Generic Drugs, general patent reform and settlement issues, general follow-on-biologic issues, S 1679 Affordable Health Choices Act, HR 3961Medicare Physician Payment Reform Act of 2009; S 1796 America's Healthy Future Act of 2009; HR 3962 Affordable Health Care for America Act; HR 3590 Senate Leadership's Health Care Overhaul; S 1504 Notice of Pleading Restoration Act of 2009
340B Program Improvement and Integrity Act of 2009
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
HR. 444 340B Program Improvement and Integrity Act of 2009, HR 684/S 330 The Medicare Prescription Drug Savings and Choice Act of 2009, HR 904 Medicaid Prescription Drug Rebate Equalization Act of 2009, Part D general issues, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform (see HCR bills); S 7, Generics First Act of 2009; End Stage Renal Disease proposed rules; TRICARE, HR 3590/4872
Foreign Manufacturers Legal Accountability Act of 2010
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
HR 759 Food and Drug Administration Globalization Act of 2009, S. 525 Pharmaceutical Market Access and Drug Safety Act of 2009 and General Importation issues, H.R. 2749 Food Safety Safety Enhancement Act, S. 882 The Drug and Device Accountability Act of 2009, Prescription Drug User Fee Act of 2012 preparation, general pedigree and chain drug supply issues, HR 4678 Foreign Manufacturers Legal Accountiblity Act; H.R. 6543 The Drug Safety Enhancement Act
Foreign Manufacturers Legal Accountability Act of 2010
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
HR 759 Food and Drug Administration Globalization Act of 2009, S. 525 Pharmaceutical Market Access and Drug Safety Act of 2009 and General Importation issues, H.R. 2749 Food Safety Safety Enhancement Act, S. 882 The Drug and Device Accountability Act of 2009, Prescription Drug User Fee Act of 2012 preparation, general pedigree and chain drug supply issues, HR 4678 Foreign Manufacturers Legal Accountiblity Act
Foreign Manufacturers Legal Accountability Act of 2010
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
S. 369 Preserve Access to Affordable Generics Act; HR 573 FDCA to prohibit the marketing of authorized generic drugs Act; Importation issues, S. 1232 Preserve Access to Affordable Generics Act; HR 5175 DISCLOSE Act; HR 4678 Foreign Manufacturers Legal Accountiblity Act ; S525 Pharmaceutical Market Access & Drug Safety
Foreign Manufacturers Legal Accountability Act of 2010
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
S. 369 Preserve Access to Affordable Generics Act; HR 573 FDCA to prohibit the marketing of authorized generic drugs Act; General Importation issues, S. 1232 Preserve Access to Affordable Generics Act; Senators McCain, Vitter and Dorgan Importation amendments and various bills, Homeland Security Department and Justice Department Appropriations bills, HR 5175 DISCLOSE Act; HR 4678 Foreign Manufacturers Legal Accountiblity Act ; S525 Pharmaceutical Market Access & Drug Safety
DISCLOSE Act
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
S. 369 Preserve Access to Affordable Generics Act; HR 573 FDCA to prohibit the marketing of authorized generic drugs Act; Importation issues, S. 1232 Preserve Access to Affordable Generics Act; HR 5175 DISCLOSE Act; HR 4678 Foreign Manufacturers Legal Accountiblity Act ; S525 Pharmaceutical Market Access & Drug Safety
DISCLOSE Act
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
S. 369 Preserve Access to Affordable Generics Act; HR 573 FDCA to prohibit the marketing of authorized generic drugs Act; General Importation issues, S. 1232 Preserve Access to Affordable Generics Act; Senators McCain, Vitter and Dorgan Importation amendments and various bills, Homeland Security Department and Justice Department Appropriations bills, HR 5175 DISCLOSE Act; HR 4678 Foreign Manufacturers Legal Accountiblity Act ; S525 Pharmaceutical Market Access & Drug Safety
DISCLOSE Act
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
S. 369 Preserve Access to Affordable Generics Act; HR 573 FDCA to prohibit the marketing of authorized generic drugs Act; General Importation issues, S. 1232 Preserve Access to Affordable Generics Act; Senators McCain, Vitter and Dorgan Importation amendments and various bills, Homeland Security Department and Justice Department Appropriations bills, HR 5175 DISCLOSE Act
Assistance, Quality, and Affordability Act of 2010
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
H.R. 1262 Water Quality Investment Act, HR 5320 The Assistance, Quality and Affordability Act,
Assistance, Quality, and Affordability Act of 2010
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
HR5320 Assistance, Quality and Affordability Act; S3397 Secure and Responsible Drug Disposal Act; HR 5809 Safe Drug Disposal Act
To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs.
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
S. 369 Preserve Access to Affordable Generics Act; HR 573 FDCA to prohibit the marketing of authorized generic drugs Act; General Importation issues, S. 1232 Preserve Access to Affordable Generics Act; Senators McCain, Vitter and Dorgan Importation amendments and various bills, Homeland Security Department and Justice Department Appropriations bills, HR 5175 DISCLOSE Act; HR 4678 Foreign Manufacturers Legal Accountiblity Act ; S525 Pharmaceutical Market Access & Drug Safety
To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs.
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
S. 369 Preserve Access to Affordable Generics Act; HR 573 FDCA to prohibit the marketing of authorized generic drugs Act; Importation issues, S. 1232 Preserve Access to Affordable Generics Act; HR 5175 DISCLOSE Act; HR 4678 Foreign Manufacturers Legal Accountiblity Act ; S525 Pharmaceutical Market Access & Drug Safety
To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs.
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
S. 369 Preserve Access to Affordable Generics Act; HR 573 FDCA to prohibit the marketing of authorized generic drugs Act; S. 501 Fair Prescription Drug Competition Act, S. 525 Pharmaceutical Market Access and Drug Safety Act of 2009 and General Importation issues, S. 1232 Preserve Access to Affordable Generics Act; Senators McCain, Vitter and Dorgan Importation amendments and various bills, Homeland Security Department and Justice Department Appropriations bills.
To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs.
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
S. 369 Preserve Access to Affordable Generics Act; HR 573 FDCA to prohibit the marketing of authorized generic drugs Act; General Importation issues, S. 1232 Preserve Access to Affordable Generics Act; Senators McCain, Vitter and Dorgan Importation amendments and various bills, Homeland Security Department and Justice Department Appropriations bills, HR 5175 DISCLOSE Act
Lobbying Disclosure Enhancement Act
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
HR5751 Lobbying Disclosure Enhancement Act
Diesel Emissions Reduction Act of 2010
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
HR5320 Assistance, Quality and Affordability Act; S3397 Secure and Responsible Drug Disposal Act; HR 5809 Safe Drug Disposal Act
Drug Safety Enhancement Act of 2011
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
HR 759 Food and Drug Administration Globalization Act of 2009, S. 525 Pharmaceutical Market Access and Drug Safety Act of 2009 and General Importation issues, H.R. 2749 Food Safety Safety Enhancement Act, S. 882 The Drug and Device Accountability Act of 2009, Prescription Drug User Fee Act of 2012 preparation, general pedigree and chain drug supply issues, HR 4678 Foreign Manufacturers Legal Accountiblity Act; H.R. 6543 The Drug Safety Enhancement Act
Medicare Prescription Drug Savings and Choice Act of 2009
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
HR 4899 Supplemental Appropriations (340B-1 and AMP), Part D coverage gap implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform (see HCR bills); End Stage Renal Disease final rules; TRICARE, HR 684/S330 Medicare prescription drug price negotiation Act of 2010, HR 4872 Health Care Reconcilation Act of 2010, HR 3590 Patient Protection and Affordable Care Act, Tax Extenders bills, HR 904 Medicaid Prescription Drug Rebate Equalization 340B expansion; PCORI
Medicare Prescription Drug Savings and Choice Act of 2009
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
HR 4899 Supplemental Appropriations (340B-1 and AMP), Part D general issues, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform (see HCR bills); End Stage Renal Disease proposed rules; TRICARE, HR 684/S330 Medicare prescription drug price negotiation Act of 2010, HR 4872 Health Care Reconcilation Act of 2010, HR 3590 Patient Protection and Affordable Care Act, Tax Extenders bills, HR 904 Medicaid Prescription Drug Rebate Equalization
Medicare Prescription Drug Savings and Choice Act of 2009
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
HR. 444 340B Program Improvement and Integrity Act of 2009, HR 684/S 330 The Medicare Prescription Drug Savings and Choice Act of 2009, HR 904 Medicaid Prescription Drug Rebate Equalization Act of 2009, Part D general issues, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform (see HCR bills); S 7, Generics First Act of 2009; End Stage Renal Disease proposed rules; TRICARE, HR 3590/4872
Food and Drug Administration Globalization Act of 2009
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
HR 759 Food and Drug Administration Globalization Act of 2009, S. 525 Pharmaceutical Market Access and Drug Safety Act of 2009 and General Importation issues, H.R. 2749 Food Safety Safety Enhancement Act, S. 882 The Drug and Device Accountability Act of 2009, Prescription Drug User Fee Act of 2012 preparation, general pedigree and chain drug supply issues, HR 4678 Foreign Manufacturers Legal Accountiblity Act; H.R. 6543 The Drug Safety Enhancement Act
Food and Drug Administration Globalization Act of 2009
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
HR 759 Food and Drug Administration Globalization Act of 2009, S. 525 Pharmaceutical Market Access and Drug Safety Act of 2009 and General Importation issues, H.R. 2749 Food Safety Safety Enhancement Act, S. 882 The Drug and Device Accountability Act of 2009, Prescription Drug User Fee Act of 2012 preparation
Food and Drug Administration Globalization Act of 2009
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: TAKEDA PHARMACEUTICALS AMERICA, INC.
HR 759 Food and Drug Administration Globalization Act of 2009, S. 525 Pharmaceutical Market Access and Drug Safety Act of 2009 and General Importation issues, H.R. 2749 Food Safety Safety Enhancement Act, S. 882 The Drug and Device Accountability Act of 2009, Prescription Drug User Fee Act of 2012 preparation, general pedigree and chain drug supply issues
health reform and the un/underinsured and implications of ACA SCOTUS decision; chronic disease legislation (diabetes, mental health, obesity, CKD); value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; HR 5 IPAB repeal;
S. 3187, the Food and Drug Administration (FDA) Safety and Innovation Act of 2012; Drug Import Safety issues; foreign drug supply chain issues; counterfiet drugs, serialization and development of tracibility model
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
TAKEDA PHARMACEUTICALS AMERICA INC via TAKEDA PHARMACEUTICALS AMERICA, INC.
2012 · second_quarter · Q2
Importation issues; Preserve Access to Affordable Generics Act; S. 319 Pharmaceutical Market Access and Drug Safety Act; Drug Import Safety issues; foreign drug supply chain issues; counterfiet drugs, serialization and development of tracibility model
Implications of ACA and Supreme Court decision; depression Rx access in Medicare, Medicaid, DOD, VA; lack of obesity Rx access in Part D;
S. 3187, the Food and Drug Administration (FDA) Safety and Innovation Act of 2012; Drug Import Safety issues; foreign drug supply chain issues; counterfiet drugs, serialization and development of tracibility model
health reform and the un/underinsured and implications of ACA SCOTUS decision; chronic disease legislation (diabetes, mental health, obesity, CKD); value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; HR 5 IPAB repeal;
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
TAKEDA PHARMACEUTICALS AMERICA INC via TAKEDA PHARMACEUTICALS AMERICA, INC.
2012 · first_quarter · Q1
General comparative effectiveness issues, health reform and the un/underinsured, chronic disease legislation (diabetes, mental health, obesity, CKD, value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; PCORI; Essential benefits package, ESRD bundling implementation; coverage gap, S. 371/HR741 Bill to prohibit authorized generics,
President Obamas Budget Proposal for FY 2013; Ryans budget
Importation issues; Preserve Access to Affordable Generics Act; S. 319 Pharmaceutical Market Access and Drug Safety Act; S. 319 Pharmaceutical Market Access and Drug Safety Act; Drug Import Safety issues; foreign drug supply chain issues
Prescription Drug User Fee Act Reauthorization; FDA Sentinel Pilot; S. 319 Pharmaceutical Market Access and Drug Safety Act; H.R.2245, Preserving Access to Life-Saving Medications Act of 2011; DTC advertising; HR 1483 Drug Import Safety legislation; drug pedigree, U.S. and foreign supply chain and drug shortage issues; Safeguarding Americas Pharmaceuticals Act; counterfiet and serialization; labeling, Best Pharmaceuticals Research Act, Pediatric Research Equity Act, Accelerated approvals, TREAT Act
Implementaton of ACA Pharmaceutical fee; corporate tax reform, R&D tax credit extension; Debt commissions recommendations; Reid/Baucus Lundgren repeal of Patient Protection and Affordable Care Act; Innovate America Act; Ryan Roadmap; Debt and deficit negotiations; foreign tax reforms; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; S. 1577 R&D Credit Bill; Camp International Tax Reform draft; Tax Relief and Job Creation Act of 2012 (H.R. 3630);
340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; Debt and deficit negotiations S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; the Medicaid Improvement and State Empowerment Act; Academic Detailing; S. 1699 Prescription Drug Cost Reduction Act; HR 3765 Temporary Payroll Tax Cut Continuation Act; HR 3765 Conflict of interest provisions; Tax Relief and Job Creation Act of 2012 (H.R. 3630); Cong. Ryan and President Obama budget proposals
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), SENATE, Treasury, Dept of
TAKEDA PHARMACEUTICALS AMERICA INC via TAKEDA PHARMACEUTICALS AMERICA, INC.
2011 · fourth_quarter · Q4
S. 23 Patent Reform Act of 2011; S. 27 Preserve Access to Affordable Generics; general patent settlement issues; HR 1249, America Invents Act; S. 968, the PROTECT IP Act
Agriculture; Labor, HHS; Commerce and Homeland Security Departments Appropriation Bills; Continuing Resolution; Budget Control Act of 2011; Joint Committee on Deficit Reduction; HR 3671 and HR 2112 Consolidated Appropriations Acts;
Prescription Drug User Fee Act Reauthorization; FDA Sentinel Pilot; S. 319 Pharmaceutical Market Access and Drug Safety Act; H.R.2245, Preserving Access to Life-Saving Medications Act of 2011; DTC advertising; HR 1483 Drug Import Safety legislation; drug pedigree, supply chain/shortage issues; Safeguarding Americas Pharmaceuticals Act; counterfiet and serialization;
Importation issues; Preserve Access to Affordable Generics Act; S. 319 Pharmaceutical Market Access and Drug Safety Act;
Implementaton of ACA Pharmaceutical fee; corporate tax reform, R&D tax credit extension; Debt commissions recommendations; Reid/Baucus Lundgren repeal of Patient Protection and Affordable Care Act; Innovate America Act; Ryan Roadmap; Debt and deficit negotiations; foreign tax reforms; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; S. 1577 R&D Credit Bill; Camp International Tax Reform draft
General comparative effectiveness issues, health reform and the un/underinsured, chronic disease legislation (diabetes, mental health, obesity, CKD), value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; PCORI; Essential benefits package, ESRD bundling implementation; coverage gap, S. 371/HR741 Bill to prohibit authorized generics, Debt and Deficit negotiations
340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; Debt and deficit negotiations S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; the Medicaid Improvement and State Empowerment Act; Academic Detailing; S. 1699 Prescription Drug Cost Reduction Act; HR 3765 Temporary Payroll Tax Cut Continuation Act; HR 3765 Conflict of interest provisions
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), SENATE, Treasury, Dept of
TAKEDA PHARMACEUTICALS AMERICA INC via TAKEDA PHARMACEUTICALS AMERICA, INC.
2011 · third_quarter · 3A
Prescription Drug User Fee Act Reauthorization; FDA Sentinel Pilot; S. 319 Pharmaceutical Market Access and Drug Safety Act; H.R.2245, Preserving Access to Life-Saving Medications Act of 2011; DTC advertising; HR 1483 Drug Import Safety legislation; drug pedigree, supply chain/shortage issues; Safeguarding Americas Pharmaceuticals Act; counterfiet and serialization;
Importation issues; Preserve Access to Affordable Generics Act; S. 319 Pharmaceutical Market Access and Drug Safety Act;
General comparative effectiveness issues, health reform and the un/underinsured, chronic disease legislation (diabetes, mental health, obesity, CKD), value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; PCORI; Essential benefits package, ESRD bundling implementation; coverage gap, S. 371/HR741 Bill to prohibit authorized generics, Debt and Deficit negotiations
S. 23 Patent Reform Act of 2011; S. 27 Preserve Access to Affordable Generics; general patent settlement issues; HR 1249, America Invents Act; S. 968, the PROTECT IP Act
340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; Debt and deficit negotiations S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; the Medicaid Improvement and State Empowerment Act; Academic Detailing;
Regenerative Medicines Promotion Act; Gastrointestinal and Motility Disorders Research Enhancement Act (H.R. 2239); depression screening, end stage renal disease;
Agriculture; Labor, HHS; Commerce and Homeland Security Departments Appropriation Bills; Continuing Resolution; Budget Control Act of 2011; Joint Committee on Deficit Reduction
Implementaton of ACA Pharmaceutical fee; corporate tax reform, R&D tax credit extension; Debt commissions recommendations; Reid/Baucus Lundgren repeal of Patient Protection and Affordable Care Act; Innovate America Act; Ryan Roadmap; Debt and deficit negotiations; foreign tax reforms; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; S. 1577 R&D Credit Bill
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), SENATE, Treasury, Dept of
TAKEDA PHARMACEUTICALS AMERICA INC via TAKEDA PHARMACEUTICALS AMERICA, INC.
2011 · third_quarter · 3A
General comparative effectiveness issues, health reform and the un/underinsured, chronic disease legislation (diabetes, mental health, obesity, CKD), value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; PCORI; Essential benefits package, ESRD bundling implementation; coverage gap, S. 371/HR741 Bill to prohibit authorized generics, Debt and Deficit negotiations
Prescription Drug User Fee Act Reauthorization; FDA Sentinel Pilot; S. 319 Pharmaceutical Market Access and Drug Safety Act; H.R.2245, Preserving Access to Life-Saving Medications Act of 2011; DTC advertising; HR 1483 Drug Import Safety legislation; drug pedigree, supply chain/shortage issues; Safeguarding Americas Pharmaceuticals Act; counterfiet and serialization;
TAKEDA PHARMACEUTICALS AMERICA INC via TAKEDA PHARMACEUTICALS AMERICA, INC.
2011 · third_quarter · Q3
340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; Debt and deficit negotiations S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; the Medicaid Improvement and State Empowerment Act; Academic Detailing;
Importation issues; Preserve Access to Affordable Generics Act; S. 319 Pharmaceutical Market Access and Drug Safety Act;
TAKEDA PHARMACEUTICALS AMERICA INC via TAKEDA PHARMACEUTICALS AMERICA, INC.
2011 · first_quarter · 1A
Implementaton of ACA Pharmaceutical fee; corporate tax reform, R&D tax credit extension; Debt and deficit commission recommendations; Reid/Baucus Lundgren repeal of Patient Protection and Affordable Care Act section 9006, referred to as 1099 provision; Innovate America Act; Ryan Roadmap;
5th Continuing Resolution HJRes44; 6th Continuing Resolution HJRes48; Department of Defense and Further Additional Continuing Appropriations Act, 2011 H1363; Department of Defense and Full-Year Continuing Appropriations Act, 2011 H1473;
340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap ;
TAKEDA PHARMACEUTICALS AMERICA INC via TAKEDA PHARMACEUTICALS AMERICA, INC.
2011 · second_quarter · Q2
Importation issues; Preserve Access to Affordable Generics Act; S. 319 Pharmaceutical Market Access and Drug Safety Act;
Prescription Drug User Fee Act Reauthorization; FDA Sentinel Pilot; S. 319 Pharmaceutical Market Access and Drug Safety Act; H.R.2245, Preserving Access to Life-Saving Medications Act of 2011; DTC advertising; HR 1483 Drug Import Ssafety legislation;
S. 23 Patent Reform Act of 2011; S. 27 Preserve Access to Affordable Generics; general patent settlement issues; HR 1249, America Invents Act; S. 968, the PROTECT IP Act
TAKEDA PHARMACEUTICALS AMERICA INC via TAKEDA PHARMACEUTICALS AMERICA, INC.
2011 · first_quarter · Q1
General comparative effectiveness issues, health reform and the un/underinsured, chronic disease legislation (diabetes, mental health, obesity, CKD), value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; PCORI; Essential benefits package, ESRD bundling implementation; coverage gap, S. 371/HR741 Bill to prohibit authorized generics, HR 2, Repealing the Job-Killing Health Care Law ; Office of Consumer Information and Insurance Oversight; Essential Benefits Committee; Comparative Effectiveness; Patient Centered Outcomes Research Institute
Importation issues, Preserve Access to Affordable Generics Act; S. 319 Pharmaceutical Market Access and Drug Safety Act;
TAKEDA PHARMACEUTICALS AMERICA INC via TAKEDA PHARMACEUTICALS AMERICA, INC.
2010 · fourth_quarter · Q4
HR 3590 Patient Protection and Affordable Care Act; International tax implications and potential corporate tax reform; Research and Development tax credit and Extenders bills, HR 4872 Health Care and Education Reconcilation Act, HR 3962, HR 4213 The American Jobs & Closing Tax Loophole Act; The Tax Relief, Unemployment Insurance Reauthorization, and Job Creation Act of 2010 (the Act); R&D tax credit; daycare center tax credit; Individual tax credits; Pharmaceutical fee
HR 4872 Health Care Reconcilation Act of 2010, HR 3590 Patient Protection and Affordable Care Act, general comparative effectiveness issues, general health reform and the un/underinsured, general diabetes legislation, mental health parity, value based insurance design, quality of care, adhereance, HR 4899 Supplemental Approprations, HCR implementation; Anit-Gout USP matters; Comparative Effectiveness/PCORI; Essential benefits package, ESRD bundling implementation; coverage gap
TAKEDA PHARMACEUTICALS AMERICA INC via TAKEDA PHARMACEUTICALS AMERICA, INC.
2010 · third_quarter · Q3
HR 4899 Supplemental Appropriations (340B-1 and AMP), Part D general issues, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform (see HCR bills); End Stage Renal Disease proposed rules; TRICARE, HR 684/S330 Medicare prescription drug price negotiation Act of 2010, HR 4872 Health Care Reconcilation Act of 2010, HR 3590 Patient Protection and Affordable Care Act, Tax Extenders bills, HR 904 Medicaid Prescription Drug Rebate Equalization
HR5320 Assistance, Quality and Affordability Act; S3397 Secure and Responsible Drug Disposal Act; HR 5809 Safe Drug Disposal Act
TAKEDA PHARMACEUTICALS AMERICA INC via TAKEDA PHARMACEUTICALS AMERICA, INC.
2010 · second_quarter · Q2
HR 3590 Patient Protection and Affordable Care Act; International tax implications and potential corporate tax reform; Economic Substance Doctrine and tax treatment of U.S. Treaty countries, Research and Development tax credit and Extenders bills, HR 4872 Health Care and Education Reconcilation Act, HR 3962, HR 4213 The American Jobs & Closing Tax Loophole Act
S. 369 Preserve Access to Affordable Generics Act; HR 573 FDCA to prohibit the marketing of authorized generic drugs Act; General Importation issues, S. 1232 Preserve Access to Affordable Generics Act; Senators McCain, Vitter and Dorgan Importation amendments and various bills, Homeland Security Department and Justice Department Appropriations bills, HR 5175 DISCLOSE Act
TAKEDA PHARMACEUTICALS AMERICA INC via TAKEDA PHARMACEUTICALS AMERICA, INC.
2010 · first_quarter · Q1
H.R. 1262 Water Quality Investment Act
S. 301 Physician Payment Sunshine Act, S. 537 Sunshine in Litigation Act, S. 623 The Pre-existing Condition Patient Protection Act, H.R. 427 Promoting Innovation and Access to Life-Saving Medicine Act, H.R. 1548 Pathway for Biosimilars Act, S. 726 Licensing of Biosimilar/Biogeneric Products, general comparative effectiveness issues, general health reform and the un/underinsured, general diabetes legislation, HR 4872 Health Care Reconcilation Act of 2010, HR 3590 Patient Protection and Affordable Care Act S 1679 Affordable Health Choices Act; HR 3961Medicare Physician Payment Reform Act of 2009; S 1796 America's Healthy Future Act of 2009; HR 3962 Affordable Health Care for America Act; HR 3590 Senate Leadership's Health Care Overhaul; H.R. 1995 Eliminating Disparities in Diabetes Prevention Access and Care Act of 2009, FTC Report "Emerging Health Care Issues: Follow-on Bilogic Drug Competition," mental health parity, value based insurance design, quality of care, adhereance.
TAKEDA PHARMACEUTICALS AMERICA INC via TAKEDA PHARMACEUTICALS AMERICA, INC.
2009 · second_quarter · 2A
S. 515, S. 610 and HR 1260 Patent Reform Acts; H.R. 427 Promoting Innovation and Access to Live-saving Medicine Act, HR 1548 Pathway for Biosimilars Act, S. 726 Licensing of biosimilar/biogeneric products, H.R. 1706 Protecting Consumer Access to Generic Drugs, general patent reform and settlement issues, general follow-biologic issues
H.R. 1346/S. 540 The Medical Device Safety Act
H.R. 1262 Water Quality Investment Act
TAKEDA PHARMACEUTICALS AMERICA INC via TAKEDA PHARMACEUTICALS AMERICA, INC.
2009 · second_quarter · Q2
S. 515, S. 610 and HR 1260 Patent Reform Acts; H.R. 427 Promoting Innovation and Access to Live-saving Medicine Act, HR 1548 Pathway for Biosimilars Act, S. 726 Licensing of biosimilar/biogeneric products, H.R. 1706 Protecting Consumer Access to Generic Drugs, general patent reform and settlement issues, general follow-biologic issues
HR 759 Food and Drug Administration Globalization Act of 2009, S. 525 Pharmaceutical Market Access and Drug Safety Act of 2009 and General Importation issues, H.R. 2749 Food Safety Safety Enhancement Act, S. 882 The Drug and Device Accountability Act of 2009
TAKEDA PHARMACEUTICALS AMERICA INC via TAKEDA PHARMACEUTICALS AMERICA, INC.
2009 · first_quarter · 1A
TRICARE Regulations
H.R. 1 The American Recover and Reinvestment Act; President Obama's Budget of the United States Government Fiscal Year 2010; H.Con.Res 85/S.Con.Res 13 Concurrent Resolution on the Budget for FY2010
H.R. 1 The American Recovery and Reinvestment Act, S. 301 Physician Payment Sunshine Act, S. 537 Sunshine in Litigation Act, S. 623 The Pre-existing Condition Patient Protection Act, H.R. 427 Promoting Innovation and Access to Life-Saving Medicine Act, HR 1548 Pathway for Biosimilars Act, S. 726 Licensing of Biosimilar/Biogeneric Products, general comparative effectiveness issues, general health reform and the un/underinsured, general diabetes legislation
TAKEDA PHARMACEUTICALS AMERICA INC via TAKEDA PHARMACEUTICALS AMERICA, INC.
2009 · fourth_quarter · Q4
S. 301 Physician Payment Sunshine Act, S. 537 Sunshine in Litigation Act, S. 623 The Pre-existing Condition Patient Protection Act, H.R. 427 Promoting Innovation and Access to Life-Saving Medicine Act, H.R. 1548 Pathway for Biosimilars Act, S. 726 Licensing of Biosimilar/Biogeneric Products, general comparative effectiveness issues, general health reform and the un/underinsured, general diabetes legislation, S 1679 Affordable Health Choices Act; HR 3961Medicare Physician Payment Reform Act of 2009; S 1796 America's Healthy Future Act of 2009; HR 3962 Affordable Health Care for America Act; HR 3590 Senate Leadership's Health Care Overhaul; H.R. 1995 Eliminating Disparities in Diabetes Prevention Access and Care Act of 2009, FTC Report "Emerging Health Care Issues: Follow-on Bilogic Drug Competition," mental health parity, value based insurance design, quality of care, adhereance.
H.R. 1346/S. 540 The Medical Device Safety Act
TAKEDA PHARMACEUTICALS AMERICA INC via TAKEDA PHARMACEUTICALS AMERICA, INC.
2009 · fourth_quarter · RA
General pharmacutical issues
General pharmacutical issues
General pharmacutical issues
TAKEDA PHARMACEUTICALS AMERICA INC via TAKEDA PHARMACEUTICALS AMERICA, INC.
2009 · third_quarter · Q3
H.R. 1262 Water Quality Investment Act
HR. 444 340B Program Improvement and Integrity Act of 2009, HR 684/S 330 The Medicare Prescription Drug Savings and Choice Act of 2009, HR 904 Medicaid Prescription Drug Rebate Equalization Act of 2009, Part D general issues, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform, H.R. 3200/S. _____ America's Affordable Health Choices Act of 2009 and Senate Finance Committee Roundtable health reform options
HR 759 Food and Drug Administration Globalization Act of 2009, S. 525 Pharmaceutical Market Access and Drug Safety Act of 2009 and General Importation issues, H.R. 2749 Food Safety Safety Enhancement Act, S. 882 The Drug and Device Accountability Act of 2009
TAKEDA PHARMACEUTICALS AMERICA INC via TAKEDA PHARMACEUTICALS AMERICA, INC.
2009 · second_quarter · Q2
S. 301 Physician Payment Sunshine Act, S. 537 Sunshine in Litigation Act, S. 623 The Pre-existing Condition Patient Protection Act, H.R. 427 Promoting Innovation and Access to Life-Saving Medicine Act, H.R. 1548 Pathway for Biosimilars Act, S. 726 Licensing of Biosimilar/Biogeneric Products, general comparative effectiveness issues, general health reform and the un/underinsured, general diabetes legislation, H.R. 3200/S. _____ America's Affordable Health Choices Act of 2009 and Senate Finance health reformoptions H.R. 1995 Eliminating Disparities in Diabetes Prevention Access and Care Act of 2009, FTC Report "Emerging Health Care Issues: Follow-on Bilogic Drug Competition," mental health parity, value based insurance design
HR. 444 340B Program Improvement and Integrity Act of 2009, HR 684/S 330 The Medicare Prescription Drug Savings and Choice Act of 2009, HR 904 Medicaid Prescription Drug Rebate Equalization Act of 2009, Part D general issues, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform, H.R. 3200/S. _____ America's Affordable Health Choices Act of 2009 and Senate Finance Committee Roundtable health reform options,
TAKEDA PHARMACEUTICALS AMERICA INC via TAKEDA PHARMACEUTICALS AMERICA, INC.
2009 · first_quarter · Q1
H.R. 1 The American Recovery and Reinvestment Act, S. 301 Physician Payment Sunshine Act, S. 537 Sunshine in Litigation Act, S. 623 The Pre-existing Condition Patient Protection Act, H.R. 427 Promoting Innovation and Access to Life-Saving Medicine Act, HR 1548 Pathway for Biosimilars Act, S. 726 Licensing of Biosimilar/Biogeneric Products, general comparative effectiveness issues, general health reform and the un/underinsured, general diabetes legislation
HR 759 Food and Drug Administration Globalization Act of 2009, S. 525 Pharmaceutical Market Access and Drug Safety Act of 2009 and General Importation issues
TAKEDA PHARMACEUTICALS AMERICA INC via TAKEDA PHARMACEUTICALS AMERICA, INC.
2008 · fourth_quarter · Q4
Federal Preemption amendments
General Food and Drug Globalization Act draft bills, S3049 Drug and Device Accountability Act
General Part D related issues; S3101, S3118, HR6331, HR6800 Medicare Improvement Acts; Least Costly Alternative; Mental Health Parity; MedPAC advisory opinions, HR976/HR 2963 Children's Health Insurance Program Reauthorization Act, HR 3162 Children's Health Medicare Protection (CHAMP), Comparative Effectiveness and general coverage issues
TAKEDA PHARMACEUTICALS AMERICA INC via TAKEDA PHARMACEUTICALS AMERICA, INC.
2008 · third_quarter · Q3
Research and Development Tax Credit; other foreign related tax issues; Tax Extenders packages
General diabetes legislative initiatives; Food and Drug Globalization Inspection bills; Uninsured and health reform issues; HR1038, HR5629, S1505, S1695 Follow On Biologics; HR6898 Health Information Technology; HR1424 Mental Health Equity Act; S1389, HR1113 Inflammatory Bowel Disease Research Act; HR3195 ADA Amendment Act; Evidence Based Medicine and Quality issues; S S3408 Comparative Effectiveness Research Act
Importation amendments, HHS funding levels in S3203 Labor, HHS, Education Appropriations Bill; H6947 and S3181 Homeland Security Appropriations Bills; S3289 Agriculture Appriations Bill; H2638 Consolidated Security, Disaster Assistance, and Continuing Appropriations Act
TAKEDA PHARMACEUTICALS AMERICA INC via TAKEDA PHARMACEUTICALS AMERICA, INC.
2008 · second_quarter · Q2
All diabetes related legislation and federal programs; Food and Drug Globalization Acts; HR 2029 Sunshine Act; HR 1424 Mental Health Equity Act; FDA Endocrinology Advisory Committee; General health care reform bills and proposals; S 1389, HR 1113 Inflammatory Bowel Disease Research Act, HR 3195 ADA Amendments Act
Food and Drug Globalization draft bills
Food and Drug Globalization draft legislation; HR 8539 Safeguarding America's Pharmaceuticals Act;
TAKEDA PHARMACEUTICALS AMERICA INC via TAKEDA PHARMACEUTICALS AMERICA, INC.
2008 · first_quarter · RA
General pharmacutical issues
General pharmacutical issues
General pharmacutical issues
TAKEDA PHARMACEUTICALS AMERICA INC via TAKEDA PHARMACEUTICALS AMERICA, INC.
2008 · first_quarter · RA
General pharmaceutical issues
General pharmaceutical issues
General pharmaceutical issues
Implementaton of ACA Pharmaceutical fee; corporate tax reform, R&D tax credit extension; Debt commissions recommendations; Reid/Baucus Lundgren repeal of Patient Protection and Affordable Care Act; Innovate America Act; Ryan Roadmap; Debt and deficit negotiations; foreign tax reforms; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; S. 1577 R&D Credit Bill
Importation issues; Preserve Access to Affordable Generics Act; S. 319 Pharmaceutical Market Access and Drug Safety Act;
S. 23 Patent Reform Act of 2011; S. 27 Preserve Access to Affordable Generics; general patent settlement issues; HR 1249, America Invents Act; S. 968, the PROTECT IP Act
340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; Debt and deficit negotiations S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; the Medicaid Improvement and State Empowerment Act; Academic Detailing;
Agriculture; Labor, HHS; Commerce and Homeland Security Departments Appropriation Bills; Continuing Resolution; Budget Control Act of 2011; Joint Committee on Deficit Reduction
Regenerative Medicines Promotion Act; Gastrointestinal and Motility Disorders Research Enhancement Act (H.R. 2239); depression screening, end stage renal disease;
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), SENATE, Treasury, Dept of
S. 23 Patent Reform Act of 2011; S. 27 Preserve Access to Affordable Generics; general patent settlement issues; HR 1249, America Invents Act; S. 968, the PROTECT IP Act
Regenerative Medicines Promotion Act; Gastrointestinal and Motility Disorders Research Enhancement Act (H.R. 2239); depression screening, end stage renal disease;
Agriculture; Labor, HHS; Commerce and Homeland Security Departments Appropriation Bills; Continuing Resolution; Budget Control Act of 2011; Joint Committee on Deficit Reduction
Implementaton of ACA Pharmaceutical fee; corporate tax reform, R&D tax credit extension; Debt commissions recommendations; Reid/Baucus Lundgren repeal of Patient Protection and Affordable Care Act; Innovate America Act; Ryan Roadmap; Debt and deficit negotiations; foreign tax reforms; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; S. 1577 R&D Credit Bill
Prescription Drug User Fee Act Reauthorization; FDA Sentinel Pilot; S. 319 Pharmaceutical Market Access and Drug Safety Act; H.R.2245, Preserving Access to Life-Saving Medications Act of 2011; DTC advertising; HR 1483 Drug Import Safety legislation; drug pedigree, supply chain/shortage issues; Safeguarding Americas Pharmaceuticals Act; counterfiet and serialization;
General comparative effectiveness issues, health reform and the un/underinsured, chronic disease legislation (diabetes, mental health, obesity, CKD), value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; PCORI; Essential benefits package, ESRD bundling implementation; coverage gap, S. 371/HR741 Bill to prohibit authorized generics, Debt and Deficit negotiations
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), SENATE, Treasury, Dept of
S. 23 Patent Reform Act of 2011; S. 27 Preserve Access to Affordable Generics
Prescription Drug User Fee Act Reauthorization; FDA Sentinel Pilot; S. 319 Pharmaceutical Market Access and Drug Safety Act;
S. 3036 National Alzheimers Project Act
Importation issues, Preserve Access to Affordable Generics Act; S. 319 Pharmaceutical Market Access and Drug Safety Act;
HR 816 Provider Shield Act of 2011 Medical malpractice reforms
General comparative effectiveness issues, health reform and the un/underinsured, chronic disease legislation (diabetes, mental health, obesity, CKD), value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; PCORI; Essential benefits package, ESRD bundling implementation; coverage gap, S. 371/HR741 Bill to prohibit authorized generics, HR 2, Repealing the Job-Killing Health Care Law ; Office of Consumer Information and Insurance Oversight; Essential Benefits Committee; Comparative Effectiveness; Patient Centered Outcomes Research Institute
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), SENATE, Treasury, Dept of
Agriculture; Labor, HHS; Commerce and Homeland Security Departments Appropriation Bills
340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; Debt and deficit negotiations S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; the Medicaid Improvement and State Empowerment Act
Implementaton of ACA Pharmaceutical fee; corporate tax reform, R&D tax credit extension; Debt commissions recommendations; Reid/Baucus Lundgren repeal of Patient Protection and Affordable Care Act; Innovate America Act; Ryan Roadmap; Debt and deficit negotiations; foreign tax reforms; HR. 2190/S.1206 Medicare Drug Savings Act of 2011
Regenerative Medicines Promotion Act; Gastrointestinal and Motility Disorders Research Enhancement Act (H.R. 2239)
General comparative effectiveness issues, health reform and the un/underinsured, chronic disease legislation (diabetes, mental health, obesity, CKD), value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; PCORI; Essential benefits package, ESRD bundling implementation; coverage gap, S. 371/HR741 Bill to prohibit authorized generics, Debt and Deficit negotiations HR 2, Repealing the Job-Killing Health Care Law ; Office of Consumer Information and Insurance Oversight; Essential Benefits Committee; Comparative Effectiveness; Patient Centered Outcomes Research Institute; S. 668 The Health Care Bureaucrats Elimination Act;
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), SENATE, Treasury, Dept of
Prescription Drug User Fee Act Reauthorization; FDA Sentinel Pilot; S. 319 Pharmaceutical Market Access and Drug Safety Act;
340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap ;
5th Continuing Resolution HJRes44; 6th Continuing Resolution HJRes48; Department of Defense and Further Additional Continuing Appropriations Act, 2011 H1363; Department of Defense and Full-Year Continuing Appropriations Act, 2011 H1473;
HR 816 Provider Shield Act of 2011 Medical malpractice reforms
S. 3036 National Alzheimers Project Act
Implementaton of ACA Pharmaceutical fee; corporate tax reform, R&D tax credit extension; Debt and deficit commission recommendations; Reid/Baucus Lundgren repeal of Patient Protection and Affordable Care Act section 9006, referred to as 1099 provision; Innovate America Act; Ryan Roadmap;
S. 23 Patent Reform Act of 2011; S. 27 Preserve Access to Affordable Generics
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), SENATE, Treasury, Dept of
HR 4899 Supplemental Appropriations (340B-1 and AMP), Part D coverage gap implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform (see HCR bills); End Stage Renal Disease final rules; TRICARE, HR 684/S330 Medicare prescription drug price negotiation Act of 2010, HR 4872 Health Care Reconcilation Act of 2010, HR 3590 Patient Protection and Affordable Care Act, Tax Extenders bills, HR 904 Medicaid Prescription Drug Rebate Equalization 340B expansion; PCORI
HR 759 Food and Drug Administration Globalization Act of 2009, S. 525 Pharmaceutical Market Access and Drug Safety Act of 2009 and General Importation issues, H.R. 2749 Food Safety Safety Enhancement Act, S. 882 The Drug and Device Accountability Act of 2009, Prescription Drug User Fee Act of 2012 preparation, general pedigree and chain drug supply issues, HR 4678 Foreign Manufacturers Legal Accountiblity Act; H.R. 6543 The Drug Safety Enhancement Act
S. 369 Preserve Access to Affordable Generics Act; HR 573 FDCA to prohibit the marketing of authorized generic drugs Act; Importation issues, S. 1232 Preserve Access to Affordable Generics Act; HR 5175 DISCLOSE Act; HR 4678 Foreign Manufacturers Legal Accountiblity Act ; S525 Pharmaceutical Market Access & Drug Safety
S. 515, S. 610 and HR 1260 Patent Reform Acts, general patent reform and settlement issues, general follow-on-biologic issues, S 1796 America's Healthy Future Act of 2009; Kerry Patent Tax amendment; HR 3590 Patient Protection and Affordable Care Act, HR 4899 House Supplemental Appropriations; Senate Financial Services Approproations mark up
HR 2997 FY 2010 Agriculture Appropriations; FY 2010 Homeland Security Department; FY 2010 Commerce State Justice Appropriations; HR 4899 House Supplemental Appropriations; Continuing Resolutions H3801, HJRes 101, HJRes 105; H3802 through 3/4/11; 2010 Debt Commission
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), SENATE, Treasury, Dept of
HR 4872 Health Care Reconcilation Act of 2010, HR 3590 Patient Protection and Affordable Care Act, general comparative effectiveness issues, general health reform and the un/underinsured, general diabetes legislation, mental health parity, value based insurance design, quality of care, adhereance, HR 4899 Supplemental Approprations, HCR implementation
HR 3590 Patient Protection and Affordable Care Act; International tax implications and potential corporate tax reform; Economic Substance Doctrine and tax treatment of U.S. Treaty countries, Research and Development tax credit and Extenders bills, HR 4872 Health Care and Education Reconcilation Act, HR 3962, HR 4213 The American Jobs & Closing Tax Loophole Act
HR5751 Lobbying Disclosure Enhancement Act
S. 515, S. 610 and HR 1260 Patent Reform Acts, general patent reform and settlement issues, general follow-on-biologic issues, S 1796 America's Healthy Future Act of 2009; Kerry Patent Tax amendment; HR 3590 Patient Protection and Affordable Care Act, HR 4899 House Supplemental Appropriations; Senate Financial Services Approproations mark up
HR 2997 FY 2010 Agriculture Appropriations; FY 2010 Homeland Security Department; FY 2010 Commerce State Justice Appropriations; HR 4899 House Supplemental Appropriations
S. 369 Preserve Access to Affordable Generics Act; HR 573 FDCA to prohibit the marketing of authorized generic drugs Act; General Importation issues, S. 1232 Preserve Access to Affordable Generics Act; Senators McCain, Vitter and Dorgan Importation amendments and various bills, Homeland Security Department and Justice Department Appropriations bills, HR 5175 DISCLOSE Act; HR 4678 Foreign Manufacturers Legal Accountiblity Act ; S525 Pharmaceutical Market Access & Drug Safety
HR 759 Food and Drug Administration Globalization Act of 2009, S. 525 Pharmaceutical Market Access and Drug Safety Act of 2009 and General Importation issues, H.R. 2749 Food Safety Safety Enhancement Act, S. 882 The Drug and Device Accountability Act of 2009, Prescription Drug User Fee Act of 2012 preparation, general pedigree and chain drug supply issues, HR 4678 Foreign Manufacturers Legal Accountiblity Act
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), SENATE
H.R. 1262 Water Quality Investment Act, HR 5320 The Assistance, Quality and Affordability Act,
HR 2997 FY 2010 Agriculture Appropriations; FY 2010 Homeland Security Department; FY 2010 Commerce State Justice Appropriations; HR 4899 House Supplemental Appropriations
HR 4899 Supplemental Appropriations (340B-1 and AMP), Part D general issues, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform (see HCR bills); End Stage Renal Disease proposed rules; TRICARE, Medicare prescription drug price negotiation Act of 2010, HR 4872 Health Care Reconcilation Act of 2010, HR 3590 Patient Protection and Affordable Care Act
H.R. 1346/S. 540 The Medical Device Safety Act
S. 515, S. 610 and HR 1260 Patent Reform Acts, general patent reform and settlement issues, general follow-on-biologic issues, S 1796 America's Healthy Future Act of 2009; Kerry Patent Tax amendment; HR 3590 Patient Protection and Affordable Care Act, HR 4899 House Supplemental Appropriations
HR 4872 Health Care Reconcilation Act of 2010, HR 3590 Patient Protection and Affordable Care Act, general comparative effectiveness issues, general health reform and the un/underinsured, general diabetes legislation, mental health parity, value based insurance design, quality of care, adhereance, HR 4899 Supplemental Approprations, HCR implementation
HR 759 Food and Drug Administration Globalization Act of 2009, S. 525 Pharmaceutical Market Access and Drug Safety Act of 2009 and General Importation issues, H.R. 2749 Food Safety Safety Enhancement Act, S. 882 The Drug and Device Accountability Act of 2009, Prescription Drug User Fee Act of 2012 preparation, general pedigree and chain drug supply issues
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), SENATE
S. 369 Preserve Access to Affordable Generics Act; HR 573 FDCA to prohibit the marketing of authorized generic drugs Act; S. 501 Fair Prescription Drug Competition Act, S. 525 Pharmaceutical Market Access and Drug Safety Act of 2009 and General Importation issues, S. 1232 Preserve Access to Affordable Generics Act; Senators McCain, Vitter and Dorgan Importation amendments and various bills, Homeland Security Department and Justice Department Appropriations bills.
S. 515, S. 610 and HR 1260 Patent Reform Acts; H.R. 427 Promoting Innovation and Access to Live-saving Medicine Act, HR 1548 Pathway for Biosimilars Act, S. 726 Licensing of biosimilar/biogeneric products, H.R. 1706 Protecting Consumer Access to Generic Drugs, general patent reform and settlement issues, general follow-on-biologic issues, S 1679 Affordable Health Choices Act, HR 3961Medicare Physician Payment Reform Act of 2009; S 1796 America's Healthy Future Act of 2009; HR 3962 Affordable Health Care for America Act; HR 3590 Senate Leadership's Health Care Overhaul; S 1504 Notice of Pleading Restoration Act of 2009
HR. 444 340B Program Improvement and Integrity Act of 2009, HR 684/S 330 The Medicare Prescription Drug Savings and Choice Act of 2009, HR 904 Medicaid Prescription Drug Rebate Equalization Act of 2009, Part D general issues, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform (see HCR bills); S 7, Generics First Act of 2009; End Stage Renal Disease proposed rules; TRICARE, HR 3590/4872
HR 759 Food and Drug Administration Globalization Act of 2009, S. 525 Pharmaceutical Market Access and Drug Safety Act of 2009 and General Importation issues, H.R. 2749 Food Safety Safety Enhancement Act, S. 882 The Drug and Device Accountability Act of 2009, Prescription Drug User Fee Act of 2012 preparation
S 1679 Affordable Health Choices Act; HR 3961Medicare Physician Payment Reform Act of 2009; S 1796 America's Healthy Future Act of 2009; HR 3962 Affordable Health Care for America Act; HR 3590 Patient Protection and Affordable Care Act; International tax implications and potential corporate tax reform; Economic Substance Doctrine and tax treatment of U.S. Treaty countries, Research and Development tax credit and Extenders bills, HR 4872 Health Care and Education Reconcilation Act
FY 2010 U.S. Treasury Green Book on Administration; H.Con.Res 85/S.Con.Res. 13 Concurrent Resolution on the Budget for FY2010; HR 2997 FY 2010 Agriculture Appropriations; FY 2010 Homeland Security Department; FY 2010 Commerce State Justice Appropriations
H.R. 1346/S. 540 The Medical Device Safety Act
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), SENATE
FY 2010 U.S. Treasury Green Book on Administration; H.Con.Res 85/S.Con.Res. 13 Concurrent Resolution on the Budget for FY2010
S. 369 Preserve Access to Affordable Generics Act; HR 573 FDCA to prohibit the marketing of authorized generic drugs Act; S. 501 Fair Prescription Drug Competition Act, S. 525 Pharmaceutical Market Access and Drug Safety Act of 2009 and General Importation issues, S. 1232 Preserve Access to Affordable Generics Act; Senator McCain Importation Amendment
HR 759 Food and Drug Administration Globalization Act of 2009, S. 525 Pharmaceutical Market Access and Drug Safety Act of 2009 and General Importation issues, H.R. 2749 Food Safety Safety Enhancement Act, S. 882 The Drug and Device Accountability Act of 2009
S. 301 Physician Payment Sunshine Act, S. 537 Sunshine in Litigation Act, S. 623 The Pre-existing Condition Patient Protection Act, H.R. 427 Promoting Innovation and Access to Life-Saving Medicine Act, H.R. 1548 Pathway for Biosimilars Act, S. 726 Licensing of Biosimilar/Biogeneric Products, general comparative effectiveness issues, general health reform and the un/underinsured, general diabetes legislation, H.R. 3200/S. _____ America's Affordable Health Choices Act of 2009 and Senate Finance health reformoptions H.R. 1995 Eliminating Disparities in Diabetes Prevention Access and Care Act of 2009, FTC Report "Emerging Health Care Issues: Follow-on Bilogic Drug Competition," mental health parity, value based insurance design
HR. 444 340B Program Improvement and Integrity Act of 2009, HR 684/S 330 The Medicare Prescription Drug Savings and Choice Act of 2009, HR 904 Medicaid Prescription Drug Rebate Equalization Act of 2009, Part D general issues, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform, H.R. 3200/S. _____ America's Affordable Health Choices Act of 2009 and Senate Finance Committee Roundtable health reform options,
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
S. 369 Preserve Access to Affordable Generics Act; HR 573 FDCA to prohibit the marketing of authorized generic drugs Act; S. 501 Fair Prescription Drug Competition Act, S. 525 Pharmaceutical Market Access and Drug Safety Act of 2009 and General Importation issues, S. 1232 Preserve Access to Affordable Generics Act; Senator McCain Importation Amendment
S. 301 Physician Payment Sunshine Act, S. 537 Sunshine in Litigation Act, S. 623 The Pre-existing Condition Patient Protection Act, H.R. 427 Promoting Innovation and Access to Life-Saving Medicine Act, H.R. 1548 Pathway for Biosimilars Act, S. 726 Licensing of Biosimilar/Biogeneric Products, general comparative effectiveness issues, general health reform and the un/underinsured, general diabetes legislation, H.R. 3200/S. _____ America's Affordable Health Choices Act of 2009 and Senate Finance health reformoptions H.R. 1995 Eliminating Disparities in Diabetes Prevention Access and Care Act of 2009, FTC Report "Emerging Health Care Issues: Follow-on Bilogic Drug Competition," mental health parity, value based insurance design
H.R. 1262 Water Quality Investment Act
H.R. 1346/S. 540 The Medical Device Safety Act
FY 2010 U.S. Treasury Green Book on Administration; H.Con.Res 85/S.Con.Res. 13 Concurrent Resolution on the Budget for FY2010
HR. 444 340B Program Improvement and Integrity Act of 2009, HR 684/S 330 The Medicare Prescription Drug Savings and Choice Act of 2009, HR 904 Medicaid Prescription Drug Rebate Equalization Act of 2009, Part D general issues, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform, H.R. 3200/S. _____ America's Affordable Health Choices Act of 2009 and Senate Finance Committee Roundtable health reform options,
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
S. 369 Preserve Access to Affordable Generics Act; HR 573 FDCA to prohibit the marketing of authorized generic drugs Act; S. 501 Fair Prescription Drug Competition Act, S. 525 Pharmaceutical Market Access and Drug Safety Act of 2009 and General Importation issues
H.R. 1262 Water Quality Investment Act
H.R. 1346/S. 540 The Medical Device Safety Act
HR 759 Food and Drug Administration Globalization Act of 2009, S. 525 Pharmaceutical Market Access and Drug Safety Act of 2009 and General Importation issues
H.R. 2 Children's Health Insurance Program Reauthorization Act of 2009, HR. 444 340B Program Improvement and Integrity Act of 2009, HR 684/S 330 The Medicare Prescription Drug Savings and Choice Act of 2009, HR 904 Medicaid Prescription Drug Rebate Equalization Act of 2009, Part D general issues, Protected Classes, Comparative Effectiveness
S. 515, S. 610 and HR 1260 Patent Reform Acts; H.R. 427 Promoting Innovation and Access to Live-saving Medicine Act, HR 1548 Pathway for Biosimilars Act, S. 726 Licensing of biosimilar/biogeneric products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
S 1679 Affordable Health Choices Act; HR 3961Medicare Physician Payment Reform Act of 2009; S 1796 America's Healthy Future Act of 2009; HR 3962 Affordable Health Care for America Act; HR 3590 Senate Leadership's Health Care Overhaul; International tax implications and potential corporate tax reform; Economic Substance Doctrine and tax treatment of U.S. Treaty countries
S. 515, S. 610 and HR 1260 Patent Reform Acts; H.R. 427 Promoting Innovation and Access to Live-saving Medicine Act, HR 1548 Pathway for Biosimilars Act, S. 726 Licensing of biosimilar/biogeneric products, H.R. 1706 Protecting Consumer Access to Generic Drugs, general patent reform and settlement issues, general follow-on-biologic issues, S 1679 Affordable Health Choices Act, HR 3961Medicare Physician Payment Reform Act of 2009; S 1796 America's Healthy Future Act of 2009; HR 3962 Affordable Health Care for America Act; HR 3590 Senate Leadership's Health Care Overhaul; S 1504 Notice of Pleading Restoration Act of 2009
HR. 444 340B Program Improvement and Integrity Act of 2009, HR 684/S 330 The Medicare Prescription Drug Savings and Choice Act of 2009, HR 904 Medicaid Prescription Drug Rebate Equalization Act of 2009, Part D general issues, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform (see HCR bills); S 7, Generics First Act of 2009; End Stage Renal Disease proposed rules; TRICARE
H.R. 1262 Water Quality Investment Act
HR 759 Food and Drug Administration Globalization Act of 2009, S. 525 Pharmaceutical Market Access and Drug Safety Act of 2009 and General Importation issues, H.R. 2749 Food Safety Safety Enhancement Act, S. 882 The Drug and Device Accountability Act of 2009
S. 369 Preserve Access to Affordable Generics Act; HR 573 FDCA to prohibit the marketing of authorized generic drugs Act; S. 501 Fair Prescription Drug Competition Act, S. 525 Pharmaceutical Market Access and Drug Safety Act of 2009 and General Importation issues, S. 1232 Preserve Access to Affordable Generics Act; Senators McCain, Vitter and Dorgan Importation amendments and various bills, Homeland Security Department and Justice Department Appropriations bills.
FY 2010 U.S. Treasury Green Book on Administration; H.Con.Res 85/S.Con.Res. 13 Concurrent Resolution on the Budget for FY2010; HR 2997 FY 2010 Agriculture Appropriations; FY 2010 Homeland Security Department; FY 2010 Commerce State Justice Appropriations
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), SENATE
General pharmacutical issues
General pharmacutical issues
General pharmacutical issues
General pharmacutical issues
General pharmacutical issues
General pharmacutical issues
H.R. 1346/S. 540 The Medical Device Safety Act
S. 369 Preserve Access to Affordable Generics Act; HR 573 FDCA to prohibit the marketing of authorized generic drugs Act; S. 501 Fair Prescription Drug Competition Act, S. 525 Pharmaceutical Market Access and Drug Safety Act of 2009 and General Importation issues, S. 1232 Preserve Access to Affordable Generics Act; Senator McCain Importation Amendments to FDA Approps Homeland Security Department and Justice Department Appropriations bills.
FY 2010 U.S. Treasury Green Book on Administration; H.Con.Res 85/S.Con.Res. 13 Concurrent Resolution on the Budget for FY2010; HR 2997 FY 2010 Agriculture Appropriations; FY 2010 Homeland Security Department; FY 2010 Commerce State Justice Appropriations
S. 301 Physician Payment Sunshine Act, S. 537 Sunshine in Litigation Act, S. 623 The Pre-existing Condition Patient Protection Act, H.R. 427 Promoting Innovation and Access to Life-Saving Medicine Act, H.R. 1548 Pathway for Biosimilars Act, S. 726 Licensing of Biosimilar/Biogeneric Products, general comparative effectiveness issues, general health reform and the un/underinsured, general diabetes legislation, H.R. 3200/S. _____ America's Affordable Health Choices Act of 2009 and Senate Finance health reformoptions H.R. 1995 Eliminating Disparities in Diabetes Prevention Access and Care Act of 2009, FTC Report "Emerging Health Care Issues: Follow-on Bilogic Drug Competition," mental health parity, value based insurance design, quality of care, adhereance.
S. 515, S. 610 and HR 1260 Patent Reform Acts; H.R. 427 Promoting Innovation and Access to Live-saving Medicine Act, HR 1548 Pathway for Biosimilars Act, S. 726 Licensing of biosimilar/biogeneric products, H.R. 1706 Protecting Consumer Access to Generic Drugs, general patent reform and settlement issues, general follow-on-biologic issues
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
S. 369 Preserve Access to Affordable Generics Act; HR 573 FDCA to prohibit the marketing of authorized generic drugs Act; S. 501 Fair Prescription Drug Competition Act, S. 525 Pharmaceutical Market Access and Drug Safety Act of 2009 and General Importation issues, S. 1232 Preserve Access to Affordable Generics Act; Senator McCain Importation Amendment
S. 515, S. 610 and HR 1260 Patent Reform Acts; H.R. 427 Promoting Innovation and Access to Live-saving Medicine Act, HR 1548 Pathway for Biosimilars Act, S. 726 Licensing of biosimilar/biogeneric products, H.R. 1706 Protecting Consumer Access to Generic Drugs, general patent reform and settlement issues, general follow-biologic issues
H.R. 1346/S. 540 The Medical Device Safety Act
H.R. 1262 Water Quality Investment Act
FY 2010 U.S. Treasury Green Book on Administration; H.Con.Res 85/S.Con.Res. 13 Concurrent Resolution on the Budget for FY2010
HR 759 Food and Drug Administration Globalization Act of 2009, S. 525 Pharmaceutical Market Access and Drug Safety Act of 2009 and General Importation issues, H.R. 2749 Food Safety Safety Enhancement Act, S. 882 The Drug and Device Accountability Act of 2009
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
TRICARE Regulations
H.R. 2 Children's Health Insurance Program Reauthorization Act of 2009, HR. 444 340B Program Improvement and Integrity Act of 2009, HR 684/S 330 The Medicare Prescription Drug Savings and Choice Act of 2009, HR 904 Medicaid Prescription Drug Rebate Equalization Act of 2009, Part D general issues, Protected Classes, Comparative Effectiveness
H.R. 1346/S. 540 The Medical Device Safety Act
H.R. 1262 Water Quality Investment Act
S. 515, S. 610 and HR 1260 Patent Reform Acts; H.R. 427 Promoting Innovation and Access to Live-saving Medicine Act, HR 1548 Pathway for Biosimilars Act, S. 726 Licensing of biosimilar/biogeneric products
S. 369 Preserve Access to Affordable Generics Act; HR 573 FDCA to prohibit the marketing of authorized generic drugs Act; S. 501 Fair Prescription Drug Competition Act, S. 525 Pharmaceutical Market Access and Drug Safety Act of 2009 and General Importation issues
H.R. 1 The American Recover and Reinvestment Act; President Obama's Budget of the United States Government Fiscal Year 2010; H.Con.Res 85/S.Con.Res 13 Concurrent Resolution on the Budget for FY2010
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Importation issues and foreign patent infringement
Food and Drug Globalization draft legislation; HR5839 Safeguarding America's Pharmaceutical Act; Importation and Pedigree issues
General diabetes legislative initiatives; Food and Drug Globalization Inspection bills; Uninsured and health reform issues; HR1038, HR5629, S1505, S1695 follow on biologic bills; HR6898 Health Information Technology; HR1424 Mental Health Equity Act; S1389, HR1113 Inflammatory Bowel Disease Research Act; HR3195 ADA Amendment Act; Evidence Based Medicine and Quality issues; general coverage issues, S3230 Labor HHS Appropriations, S.2162, HR2922, S3408, S3396
Importation amendments and HHS funding levels in S3203 Labor, HHS, Education Appropriations Bills; H6947 and S3181 Homeland Security Appropriations Bills; S3289 Agriculture Appropriations Bill; H2638 Consolidated Security, Disaster Assistance, and Continuing Appropriations Act, Economic Stimulus packages--all health related programs
HR1038, HR5629, S1505, S1695 Follow On Biologics; S3325, S4364, S3600 Patent and Intellectual Property enforcement and reform bills
Research and Development Tax Credit; other foreign related tax issues; Tax Extenders packages
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Medicare Payment Advisory Commission (MedPAC), SENATE
S3406 Americans with Diabilities Act Amendments
Food and Drug Globalization draft legislation; HR8539 Safeguarding America's Pharmaceutical Act; Importation and Pedigree issues
General Part D related issues; S3101, S3118, HR6331, HR6800 Medicare Improvement Acts; Least Costly Alternative; Mental Health Parity;
Importation issues
S3123 Foreign Lobbying Act
Federal Preemption amendments
HR1038, HR5629, S1505, S1695 Follow On Biologics; S3325, S4364, S3600 Patent and Intellectual Property enforcement and reform bills
General Food and Drug Globalization Act draft bills, S3049 Drug and Device Accountability Act
2008 National Defense Authorization Act-Tricare
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
HR 2642 Supplemental Appropriations Bill and FDA additional funding; S 3203 Labor, HHS, Education Appropriations Bill; Importation amendments
2008 National Defense Authorization Act -Tricare Program changes
S. 3101, S. 3118, HR 6331 Medicare Improvements for Patients and Providers Act of 2008; General Part D issues; Mental health issues; General Medicare/Medicaid issues
S. 3123 Foreign Lobbying Act
Food and Drug Globalization draft bills; Committee on Foreign Investments in the United States proposed regulations; Importation amendments;
S. 2041, HR 4854 False Claims Act Amendments; Federal Premption amendments
HR 1038, HR 5629, S. 1505, S. 1695 Follow On Biologics bills
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
General pharmacutical issues
General pharmacutical issues
General pharmacutical issues
General pharmaceutical issues
General pharmaceutical issues
General pharmaceutical issues